ArticleChemistry & biodiversity2026
Synthesis and Biological Evaluation of a Lipophilic Vorinostat Prodrug.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthesis and Biological Evaluation of a Lipophilic Vorinostat Prodrug.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vorinostat, a hydroxamic acid-based histone deacetylase (HDAC) inhibitor approved for cutaneous T-cell lymphoma, exhibits broad-spectrum anticancer activity. However, its clinical application is limited by poor permeability and rapid metabolism, which result in a short half-life and consequently poor therapeutic efficacy. To address these constraints, we synthesized a series of lipid-vorinostat conjugates (3a-d) through acylation of vorinostat with short-chain fatty acid chloride derivatives (2a-d). The chemical structures and purity of the conjugates (3a-d) were confirmed using NMR, HRMS, and HPLC analyses. Among these derivatives, compound 3d (3,5,5-Trimethylhexanoyl-Vorinostat) demonstrated improved cytotoxicity against A549 and 4T1 carcinoma cells. Mechanistic insight revealed that the compound 3d induced higher levels of caspase-3/7 activation, reactive oxygen species (ROS) generation, and mitochondrial membrane potential (MMP) loss compared with vorinostat, suggesting enhanced apoptosis. The cell scratch assay demonstrated that 3d markedly inhibited cell migration as compared with vorinostat. Furthermore, in silico ADMET profiling predicted enhanced membrane permeability of the compound 3d as compared to vorinostat. The in vitro plasma stability revealed time-dependent hydrolysis of compound 3d to release active vorinostat, supporting its prodrug behavior. Collectively, these findings suggest lipid conjugation as a promising prodrug strategy to modulate the biological and physicochemical properties of vorinostat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.